ArticleAnnals of African medicine2025
Clinico-epidemiological Patterns, Risk Factors, and Seroprevalence of Hepatitis C in Patients Attending a Tertiary Care Center in North India.
Article in Annals of African medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe hepatitis C virus is an important cause of chronic hepatitis and primary hepatocellular carcinomas. Early treatment of HCV infection, especially in the acute phase, can facilitate elimination of the virus and prevent chronic infection. This will limit HCV-related liver damage and mortality. This study provides the current clinical-epidemiologic pattern, risk factors and seroprevalence of hepatitis C in clinical suspected cases attending different departments of a tertiary care centre.
methodsThe study was conducted for a period of 1 year (March 2023 to March 2024) in the Department of Microbiology, AIIMS, Raebareli. After obtaining ethical clearance, serum samples were collected from all patients referred to the Department of Microbiology to determine antibodies against HCV. An ELISA was performed for anti-HCV antibodies and HBsAg. The results and relevant clinical information were noted and analysed.
resultsOf the 16911 samples, 127 (0.75%) were positive for anti-HCV antibodies. Of the 127 anti-HCV positive samples, 88 (69.3%) samples had an S/Co ratio >5.0, while 39 (30.7%) samples had an S/Co ratio <5.0. Majority of the cases were in the age group 46-60 years (31%), followed by the age group 31-45 years (26.%) and 61-75 years (26.%). The number of male cases (55.91%) was slightly higher than female cases (44.09%). In our study, serum bilirubin was elevated in 29.8% (29/127) of anti-HCV seropositive patients, alanine transaminase (ALT) was elevated in 56.7% (72/127) of seropositive patients and 49.6% (63/127) of seropositive patients had elevated aspartate transaminase (AST). A history of surgery (30.9%) was the most important risk factor in the seropositive patients.
conclusionThe study shows the seroprevalence of hepatitis C virus in patients with clinical suspicion, with 0.75% of samples testing positive for anti-HCV antibodies. Most positive cases were observed in adults aged 46-60 years, with elevated ALT and AST levels found in several seropositive patients. Surgical history has emerged as a notable risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.